Investment analysts at Rodman & Renshaw began coverage on shares of Aytu Bioscience Inc (OTC:AYTU) in a research report issued to clients and investors on Monday. The firm set a “buy” rating and a $9.00 price target on the stock. Rodman & Renshaw’s price target points to a potential upside of 168.66% from the stock’s current price.

Aytu Bioscience (OTC:AYTU) opened at 3.35 on Monday. The company’s market capitalization is $16.98 million. The firm has a 50-day moving average of $3.66 and a 200 day moving average of $4.81. Aytu Bioscience has a one year low of $3.01 and a one year high of $57.00.

Aytu Bioscience Company Profile

Aytu BioScience, Inc is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer.

Receive News & Stock Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related stocks with our FREE daily email newsletter.